Valve types, size and access site according to study phases and need for PMI
| Study phases | Low-volume (n=192) | High-volume (n=356) | Total (n=548) | P value |
| Mechanically expandable valve | ||||
| Lotus | 47 (24.5%) | 51 (14.3%) | 98 (17.9%) | p=0.003 |
| Self-expanding valve | ||||
| Corevalve | 124 (64.6%) | 5 (1.4%) | 129 (23.5%) | p<0.001 |
| Evolut R | 21 (10.9%) | 138 (38.8%) | 159 (29.0%) | p<0.001 |
| Evolut Pro | 0 (0.0%) | 54 (15.2%) | 54 (9.9%) | p<0.001 |
| Abbott Portico | 0 (0.0%) | 43 (12.1%) | 43 (7.8%) | p<0.001 |
| Balloon-expandable valve | ||||
| Edward Sapien 3 | 0 (0.0%) | 55 (15.4%) | 55 (10.0%) | p<0.001 |
| Edward Sapien 3 Ultra | 0 (0.0%) | 10 (2.8%) | 10 (1.8%) | p<0.001 |
| PMI ≤30 days after TAVI | PMI (n=173) | No PMI (n=375) | Total (n=548) | p-value |
| Valve size (mm) | 27.7±2.8 | 27.9±2.8 | 27.6±2.8 | 0.414 |
| Valve in valve | 15 (2.7%) | 1 (0.6%) | 14 (3.7%) | 0.035 |
| Access site | ||||
| Femoral | 154 (89.0%) | 326 (87.0%) | 480 (87.6%) | 0.724 |
| Subclavian | 14 (8.0%) | 31 (8.0%) | 8.0%) | |
| Direct aorta | 5 (3.0%) | 17 (5.0%) | 4.0%) | |
| Other | 0 | 1 (0.3%) | 1 (0.3%) | |
| Mechanically expandable valve | ||||
| Lotus | 58 (33.5%) | 40 (10.7%) | 98 (17.9%) | p<0.001 |
| Self-expanding valve | ||||
| Corevalve | 54 (31.2%) | 75 (20.0%) | 129 (23.5%) | p=0.004 |
| Evolut R | 39 (22.5%) | 120 (32%) | 159 (29.0%) | p=0.023 |
| Evolut Pro | 9 (5.2%) | 45 (12%) | 54 (9.9%) | p=0.013 |
| Abbott Portico | 11 (6.4%) | 32 (8.5%) | 43 (7.8%) | p=0.379 |
| Balloon expandable valve | ||||
| Edward Sapien 3 | 2 (1.2%) | 53 (14.1%) | 55 (10.0%) | p<0.001 |
| Edward Sapien 3 Ultra | 0 (0.0%) | 10 (2.7%) | 10 (1.8%) | p=0.030 |
PMI, permanent pacemaker implantation.